Eurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidate

Eurocine Vaccines AB (“Eurocine Vaccines” or the “Company”) has today selected Biovian Oy, Turku, Finland, (“Biovian”) as the contract developer for the Company’s vaccine candidate against chlamydia. Biovian, which is an internationally recognized contract developer and manufacturer with its own GMP facility, will develop an industrial manufacturing method as well as manufacture study products for Eurocine Vaccines´ future studies, such as toxicological and clinical studies.

Read More

Eurocine Vaccines advances the development of commercial manufacturing method and updates time plan

In connection with the procurement of contract manufacturer for the active protein in the chlamydia vaccine candidate, Eurocine Vaccines AB (“Eurocine Vaccines” or the “Company”) has, already at this stage, decided to develop a manufacturing method, which is suitable for the manufacture of vaccines on an industrial scale. In connection with the decision, the Company has updated the time plan.

Read More

Eurocine Vaccines´ Interim report July-September 2020

Eurocine Vaccines AB (”Eurocine Vaccines”) herby publishes the interim report for the first quarter of 2020/2021. Below is a brief summary of the interim report. The interim report is available at Euroccine Vaccines website (www.eurocine-vaccines.com/) and as an attachment.

Read More

Eurocine Vaccines AB is moved to the Observation List

Following today’s press release from Spotlight, the company’s share will be moved to Spotlight’s Observation List. Information about the share: Shortname: EUCI ISIN-code: SE0001839069 Orderbook-ID: 4102 CFI: ESVUFR FISN: EUROCINE/SH Organization number: 556566-4298 LEI: 549300B408R6FTXR0D15  Stockholm January 15, 2019 Spotlight Stock Market 08-511 68 000 info@spotlightstockmarket.com 

Read More

11/19 – Eurocine Vaccines AB is moved to the Observation List

Following today’s press release from Spotlight, the company’s share will be moved to Spotlight’s Observation List. Information about the share: Shortname: EUCI ISIN-code: SE0001839069 Orderbook-ID: 4102 CFI: ESVUFR FISN: EUROCINE/SH Organization number: 556566-4298 LEI: 549300B408R6FTXR0D15  Stockholm January 15, 2019 Spotlight Stock Market 08-511 68 000 info@spotlightstockmarket.com 

Read More

Eurocine Vaccines´ nasal influenza vaccine candidate Immunose™ FLU showed good safety in older adults

Eurocine Vaccines today announced good safety and tolerability in older adults, in the second clinical phase I/II study including their quadrivalent influenza vaccine candidate. Immunose™ FLU is a novel nose drop formulation based on the company’s technology Endocine™ and inactivated split influenza antigens. – I am very happy that we have once again confirmed good

Read More

Eurocine Vaccines has completed dosing of its quadrivalent influenza vaccine candidate, Immunose™ FLU, in the second clinical study

– In the perspective of this year’s severe influenza outburst we are pleased to have chosen the broader quadrivalent, rather than trivalent, vaccine for our product candidate, says Dr. Anna-Karin Maltais, Chief Scientific Officer. -The elderly always suffer most from influenza disease and we believe that we can offer a better and more convenient vaccine

Read More

World Vaccine Congress, Europe

Following up WVC in Washington during the spring CSO Anna-Karin Maltais and CEO Hans Arwidsson will present the latest progress from development of Immunose™ FLU, our first vaccine candidate, based on our technology platform Endocine™ This conference is about research, development and strategic partnering for the global vaccine industry. Read more here =>  

Read More

Do you want to follow Eurocine Vaccines development?

Share our ambition developing more effective vaccines. Fill in your e-mail address and we will update you with the latest Press Releases and Stories.

Start your subscription here »